78397-15-6

Usage

Uses

Used in Pharmaceutical Industry:
2-[((1R)-1-phenylethyl)amino]acetic acid is used as a precursor in the synthesis of certain pharmaceuticals for its psychoactive properties, which can be harnessed for therapeutic purposes.
Used in Research Chemicals:
It is utilized as a research chemical to study the effects of psychoactive substances and their potential applications in medicine and neuroscience.
Used in Controlled Substances Regulation:
Due to its potential for abuse and dependence, 2-[((1R)-1-phenylethyl)amino]acetic acid is used in the development and enforcement of regulations and policies related to controlled substances in various countries.

Upstream product

• 66512-37-6 (R)-ethyl 2-(1-phenylethylamino)acetate 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 83732-50-7 methyl 2-{[(1R)-1-phenylethyl]amino}acetate 

Downstream Products

• 370880-01-6 (3aS,6aS)-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,4-b]pyrrole-5-carboxylic acid ethyl ester 
• 370879-99-5 ethyl (3aR,6aR)-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydro-pyrrolo[3,2-c]pyrrole-5-carboxylate 
• 948846-55-7 ethyl 1-((R)-1-phenyl-ethyl)-hexahydro-1H-pyrrolo[2,3-c]pyrrole-5-carboxylate 
• 370880-12-9 (3aS,6aS)-1-[(1R)-1-phenylethyl]-3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[3,4-b]pyrrole 
• 99735-47-4 (3R)-1-[(R)-1-phenylethyl]-3-(hydroxymethyl)pyrrolidine 
• 370880-03-8 (3aR,6aR)-1-[(1R)-1-phenylethyl]-3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[3,2-c]pyrrole 
• 1421372-15-7 (3aR,6aR)-5-methyl-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,2-c]pyrrole 

Relevant academic research and scientific papers

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

OCTAHYDRO-PYRROLO[3,4-B]PYRROLE N-OXIDES

The invention relates to octahydro-pyrrolo[3,4-b]pyrrole N-oxides as prodrugs of CNS-active compounds, compositions comprising such compounds, methods for making the compounds, salts, and polymorphs, and methods of treating conditions and disorders using

OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES

Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making th

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Diazabicyclic central nervous system active agents

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Diazabicyclooctane derivatives

PCT No. PCT/GB96/02312 Sec. 371 Date Mar. 12, 1998 Sec. 102(e) Date Mar. 12, 1998 PCT Filed Sep. 19, 1996 PCT Pub. No. WO97/11949 PCT Pub. Date Apr. 3, 1997A class of 2,7-diazabicyclo[3.3.0]octane derivatives represented by formula I are selective agonist